Abstract

In recent years, the idea of the gut microbiota being involved in the pathogenesis of autism spectrum disorders (ASD) has attracted attention through numerous studies. Many of these studies report microbial dysregulation in the gut and feces of autistic patients and in ASD animal models. The host microbiota plays a large role in metabolism of ingested foods, and through the production of a range of metabolites it may be involved in neurodevelopmental disorders such as ASD. Two specific microbiota-derived host metabolites, p-cresol sulfate and 4-ethylphenyl sulfate, have been associated with ASD in both patients and animal models. These metabolites originate from bacterially produced p-cresol and 4-ethylphenol, respectively. p-Cresol and 4-ethylphenol are produced through aromatic amino acid fermentation by a range of commensal bacteria, most notably bacteria from the Clostridioides genus, which are among the dysregulated bacteria frequently detected in ASD patients. Once produced, these metabolites are suggested to enter the bloodstream, pass the blood–brain-barrier and affect microglial cells in the central nervous system, possibly affecting processes like neuroinflammation and microglial phagocytosis. This review describes the current knowledge of microbial dysbiosis in ASD and elaborates on the relevance and synthesis pathways of two specific ASD-associated metabolites that may form a link between the microbiota and the brain in autism. While the two discussed metabolites are promising candidates for biomarkers and (nutritional) intervention targets, more research into the role of these metabolites in ASD is required to causally connect these metabolites to ASD pathophysiology.

Highlights

  • Autism spectrum disorders (ASD) consist of a set of heterogeneous neurodevelopmental conditions, characterized by early-onset deficits in social communication and interaction, and unusually restrictive or repetitive behavior and interests (Lai et al, 2014)

  • The notion that the microbiota is in some way involved in neurodevelopmental disorders such as ASD continues to acquire evidence

  • As outlined in this review, specific microbiota-derived metabolites may form a link between the microbiota and the brain, and future studies on the effects of such metabolites may provide insights into the pathophysiology and possibly, etiology of ASD

Read more

Summary

Introduction

Autism spectrum disorders (ASD) consist of a set of heterogeneous neurodevelopmental conditions, characterized by early-onset deficits in social communication and interaction, and unusually restrictive or repetitive behavior and interests (Lai et al, 2014). Fombonne et al (2021) have recently estimated the current worldwide ASD prevalence is 1% based on a thorough epidemiological review, this makes ASD one of the most frequently occurring neurodevelopmental disorders in childhood. Autism diagnosis currently relies on behavioral evaluations, there is a need for valid and clinically useful biomarkers (Lai et al, 2014). Various psychological and educational interventions are used to address the behavioral and functional deficits that are associated with ASD (Lai et al, 2014). While no pharmacotherapies addressing the disorder itself exist, two antipsychotic drugs (risperidone and aripiprazole) are approved for the treatment of ASD-associated irritability and aggression (Leskovec et al, 2008)

Objectives
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call